Amgen’s Sell Rating: Declining EPS and Overvalued Stock Amid Modest Revenue Growth
In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...
stocknews4h
3 Biotech Stocks Revolutionizing Healthcare
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Amgen's SWOT analysis: stock outlook amid obesity drug race, pipeline progress
Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors
Shares of Bio-Techne Corp. shed 3.71% to $71.83 Wednesday, on what proved to be an all-around dismal trading session for the ...
JD Supra20h
Amgen and Celltrion Settle Denosumab BPCIA Case
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
bovnews22h
What’s Causing Amgen Inc (AMGN) Stock’s -16.29% Drop Over the Last Six Months?
Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...
Here's Why Amgen (AMGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.